שולי רווח נקי ממכירות: Ensysce Biosciences (ENSC)

Ensysce Biosciences (ENSC) is developing TAAP and MPAR safeguard systems designed to eliminate opioid overdoses. Development relies on a team of toxicology experts and US regulatory specialists. The business model is based on the full outsourcing of synthesis and testing to external vendors. An analysis of sales margin stability shows that the indicator level is -1473.70, which helps assess the company's real profitability.
פילוחי מדדים פיננסיים ומדדי שוק עבור ensysce.com (ENSC)

Conservative asset selection requires an analysis of cash flow resilience against long-term risks. Net margin measures the portion of profit in every dollar of revenue, demonstrating the ultimate efficiency of the operating model. For Ensysce Biosciences (ENSC), this metric reflects the drug development stage, where R&D costs significantly exceed occasional grants. By analyzing the net profit margin, an investor sees a predictable depletion of capital. Short-term fluctuations in this net profit margin are often driven by one-time write-offs.